Anti-NGF monoclonal antibodies represent a revolution in feline arthritis management, providing monthly injectable pain relief that bypasses the NSAID limitations of feline metabolism.
The development of anti-NGF monoclonal antibody treatments for cats with osteoarthritis represents a major advance in feline welfare, addressing a treatment gap that has left millions of arthritic cats inadequately managed for decades. NSAID use in cats is limited by their reduced ability to metabolise these drugs, creating a situation where chronic pain management was difficult and frequently inadequate. Frunevetmab provides effective, monthly pain relief with a good safety profile even in cats with compromised kidney function, opening treatment options for precisely the population of older cats most likely to have both arthritis and concurrent kidney disease. Veterinary education about the scale of feline arthritis and the availability of effective treatment is needed to translate this advance into routine welfare benefit for affected cats.